Chase Pharmaceuticals Corporation clinical trials
Acquired by AbbVie, May 8, 2020 · source ↗
The registry lists 4 studies whose lead sponsor is Chase Pharmaceuticals Corporation. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jun 4, 2020.
Before and after it joined AbbVie
- First submitted before Chase Pharmaceuticals Corporation became part of AbbVie
- 4
- First submitted after Chase Pharmaceuticals Corporation became part of AbbVie
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Chase Pharmaceuticals Corporation, an affiliate of Allergan plc4 studies
Something wrong with this grouping? Tell us on the AbbVie page.
Studies
Recruiting first, then most recently updated. Showing 4 of 4. All AbbVie studies →
- A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type DementiaCompletedNCT02185053Phase 2
Sponsor listed in the registry: Chase Pharmaceuticals Corporation, an affiliate of Allergan plc · First submitted before Chase Pharmaceuticals Corporation became part of AbbVie
- A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's TypeCompletedNCT02549196Phase 2
Sponsor listed in the registry: Chase Pharmaceuticals Corporation, an affiliate of Allergan plc · First submitted before Chase Pharmaceuticals Corporation became part of AbbVie
- Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07CompletedNCT02434666Phase 2
Sponsor listed in the registry: Chase Pharmaceuticals Corporation, an affiliate of Allergan plc · First submitted before Chase Pharmaceuticals Corporation became part of AbbVie
- CPC-201 Alzheimer's Disease Type Dementia: PET StudyWithdrawnNCT02860065Phase 2
Sponsor listed in the registry: Chase Pharmaceuticals Corporation, an affiliate of Allergan plc · First submitted before Chase Pharmaceuticals Corporation became part of AbbVie